



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/729,949

12/09/2003

Sydney M. Finegold

111828-00113

8848

27557 7590 03/03/2010
BLANK ROME LLP
WATERGATE
600 NEW HAMPSHIRE AVENUE, N.W.
WASHINGTON, DC 20037

EXAMINER

WARE, DEBORAH K

ART UNIT

PAPER NUMBER

1651

MAIL DATE

DELIVERY MODE

03/03/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/729,949	Applicant(s) FINEGOLD, SYDNEY M.	
	Examiner DEBBIE K. WARE	Art Unit 1651	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 December 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3 and 10-17 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3 and 10-17 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____. | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
5) <input type="checkbox"/> Notice of Informal Patent Application
6) <input type="checkbox"/> Other: _____. |
|--|---|

S.N. 10/729,949

ART UNIT 1651

DETAILED ACTION

Claims 1-3 and 10-17 are presented for reconsideration on the merits.

Response to Amendment

The amendment filed December 12, 2009 and July 27, 2009, have been received and entered. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3 and 10-17 are rejected under 35 U.S.C. 103(a) as obvious over newly cited Mikelsaar et al (US 7244424) in view of Borody (US 5,443,826) and Farmer et al (US 7374753) and Armel abstract, see enclosed and previously PTO-892 Forms.

Claims are drawn to a method of treating disease associated with an abnormal gastrointestinal flora (i.e. Clostridium capable of producing a toxin) selected from juvenile rheumatoid arthritis comprising administering to a patient suffering therefrom an antibacterial

agent (including an antibiotic, i.e. metronidazole, or vancomycin, etc., or bacteriophage or radionuclide). The antimicrobial composition is in the form of a tablet or capsule which is enteric coated. Claims are further drawn to a method as discussed above wherein the antibacterial agent is a radionuclide active against spores of the abnormal microbe or a bacteriophage specific for the abnormal microbe.

Mikelsaar et al teach treating disease with Lactobacillus probiotic accompanying antibiotic/antibacterial treatment (e.g. metronidazole), note col. 5, lines 28-30. Further, the probiotic is a normal, benign inhabitant of a human gut (col. 2, lines 60-65). Note col. 4, lines 45-50, wherein the abnormal microbe is a bacterium. Tablets and capsules are disclosed at col. 1, lines 15-16.

Borody teaches a method of treating disease associated with an abnormal gastrointestinal flora (i.e. Clostridium capable of producing a toxin) wherein the disease is rheumatoid arthritis or autoimmune disease. Note abstract and col. 2, line 46, and col. 7, line 35. The method includes administering to a patient suffering therefrom an antibacterial agent (i.e. Vancomycin or metronidazole, see col. 5, lines 55-60 and col. 6, line 59); and then probiotic was administered, note col. 6, lines 45-65 and note col. 7, lines 30-40. Further, administering the composition in the form of enteric-coated capsules is disclosed, see col. 5, line 1. Several desirable bacteria are disclosed in Table 1, note Bacterioides, at col. 6, line 21. Also, Borody further teaches the abnormal microorganism is a bacterium. Also the antibacterial agent can be an antibiotic and a probiotic such as Bacterioides is disclosed to be administered in addition to an antibacterial agent. The Clostridium bacterium is disclosed to produce a toxic metabolite. Further, the antimicrobial composition is in the form of an enteric coated tablet or capsule. Also the

abnormal microbe is Clostridium. The administering step includes both administering an antibiotic and probiotic for treating a disease associated with an abnormal gut flora, and the disease is selected from an autoimmune disease or rheumatoid arthritis of which can occur in young people.

Farmer et al teach bacteriophage are antibacterial because they inhibit the growth of specific bacteria, note col. 1, lines 20-25.

Armel teach control of spore-forming bacteria with radionuclides, see entire abstract only.

The claims differ from Mikelsaar et al in that rheumatoid arthritis is not specifically disclosed, nor is the abnormal microbe, Clostridium, which produces a toxin, and neither is the radionuclide or bacteriophage.

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to administer both an antibacterial agent, such as an antibiotic, like Vancomycin, and then to administer a Bacteriodes probiotic or some other one to treat an autoimmune disease like IBS or some other autoimmune disease, and to also treat arthritis, as disclosed by Mikelsaar et al and Borody, and further to include bacteriophage or radiocides as disclosed by Farmer et al and Armel. Borody clearly teach that these diseases are treatable by administering both an antibacterial agent and probiotic, and also both Mikelsaar et al and Borody teach administering both an antibiotic and subsequently a probiotic. To administer both the antibacterial agent and then a probiotic agent is clearly taught or is at least obvious over the cited Borody reference taken together with Mikelsaar et al. Thus, the claims are at least rendered obvious over the cited reference. Further, One of skill would have been motivated to

administer both the antibacterial agent and the probiotic agent with an expectation of successful results since there would be no resistance to the antibiotics.

Borody is discussed above, and further teaches the abnormal microorganism is a bacterium. Also the antibacterial agent can be an antibiotic and a probiotic such as *Bacterioides* is disclosed to be administered in addition to an antibacterial agent. The *Clostridium* bacterium is disclosed to produce a toxic metabolite. Further, the antimicrobial composition is in the form of an enteric coated tablet or capsule. Also the abnormal microbe is *Clostridium*. The administering step includes both administering an antibiotic and probiotic for treating a disease associated with an abnormal gut flora, and the disease is selected from an autoimmune disease or rheumatoid arthritis of which can occur in young people.

Furthermore, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to include as the antibacterial agents of those disclosed as having antibacterial activity by Farmer et al and the Armel abstract for a method of treating disease associated with an abnormal gastric flora selected from an autoimmune disease and/or arthritis. Clearly to select as an antibacterial agent a radionuclide or bacteriophage for use in the method of Mikelassar et al taken with Borody is an obvious choice amongst functional equivalents well recognized in the cited prior art.

One of skill would have been motivated to select a bacteriophage or radionuclide with the expectation of successful results because they are well known for their antibacterial activity. Also one of skill in the art would have been capable of determining the optimal antibacterial agent to select dependent upon the pathogenic effect desired because they are well known and taught in the cited prior art to be effective for treating pathogenic bacteria. Therefore, in the

absence of persuasive evidence to the contrary the claims are rendered prima facie obvious over the cited prior art.

Response to Arguments

Applicant's arguments filed July 27, 2009 and December 11, 2009, have been fully considered but they are not persuasive because of the newly applied art. The use of antibiotics and probiotics is clearly taught by Mikelsaar et al or is at least suggested by the above cited prior art combination. The probiotic treatment step of Mikelsaar et al clearly also includes an antibiotic treatment step. Therefore, any insufficiencies of Borody are satisfied by the teaching of the newly applied cited prior art rejection.

All claims fail to be patentably distinguishable over the state of the art discussed above and cited on the previously enclosed PTO-892 and/or PTO-1449. Therefore, the claims are properly rejected.

The remaining references listed on the previously enclosed PTO-892 and/or PTO-1449 are cited to further show the state of the art.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBBIE K. WARE whose telephone number is (571)272-0924. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Deborah K. Ware/
Deborah K. Ware
Examiner
Art Unit 1651